This Faculty Profile is inactive. The faculty member may have temporarily disabled their profile, or have recently left the University.
Information displayed here may be inaccurate and/or out-of-date.

Marylou V. Solbrig

Associate Adjunct Professor, Neurology
School of Medicine

Joint appointment, Department of Pharmacology, School of Medicine

Joint appointment, Department of Medicine, School of Medicine


M.D., Albert Einstein College of Medicine, 1980

Phone: (949) 824-6270
Fax: (949) 824-6305
Email: msolbrig@uci.edu

University of California, Irvine
3226 Gillespie Neurosciences Research Facility
Mail Code: 4292
Irvine, CA 92697

picture of Marylou V. Solbrig

   
Academic
Distinctions
National Merit Scholar, 1971
Sarah Williston Scholar (5% Mt Holyoke class), 1973
MIT Undergraduate Research Opportunities Program Grant, 1974
Albert Einstein College of Medicine Community Health Department Scholarship (medical work in Kenya), 1980
UCI Faculty Career Development Award, 1992
UCI College of Medicine Research Grant, 1993
American Cancer Society UCI Institutional Grant, 1993
Committee of 1000 Young Investigator Research Award UCI, 1995
San Diego Parkinson’s Corporation Award, 1997
Veterans Affairs Special Fellows in Neurosciences Award for Parkinson’s Disease Research, 1997-8
NIDA Mentored Clinical Scientist Development Award, 1998-2003
Elected active member American Neurological Association, 2006
   
Publications PEER-REVIEWED:
Solbrig, M.V. Sher, J.H. Kula, R.W. Rhabdomyolysis in Leptospirosis (Weil's Disease) J. Infect. Dis. 156(4):692-3 (1987)

Solbrig, M.V. Wong, M.L. Stephens, R.S. Developmental-stage-specific plasmid supercoiling in Chlamydia trachomatis. Molecular Microbiology 4(9):1535-41 (1990)

Solbrig, M.V. Headache syndromes in Sierra Leone, West Africa. Headache 31(6):419 (1991)

Solbrig, M.V. McCormick, J.B. Lassa fever: central nervous system manifestations. J. Trop. Geogr. Neurol. 1:23-30 (1991)

Solbrig, M.V. Nashef, L. Acute Parkinsonism in suspected herpes simplex encephalitis. Movement Disorders 8(2):233-4 (1993)

Solbrig, M.V. Koob, G.F. Fallon, J.H. Lipkin, W.I. Tardive dyskinetic syndrome in rats infected with Borna disease virus. Neurobiol. Dis. 1(3):111-119 (1994)

Lipkin, W.I. Schneemann, A., Solbrig, M.V. Borna disease. Trnds. Microbiol. 3 (2):64-69 (1995)

Solbrig, M.V. Koob, G.F. Lipkin, W.I. Naloxone-induced seizures in Borna disease virus-infected rats. Neurology 46:1170-1171 (1996)

Solbrig, M.V., Koob, G.F., Fallon, J.H. Reid, S. Lipkin, W.I. Prefrontal cortex dysfunction in Borna disease virus-infected rats and its relevance to schizophrenia. Biological Psychiatry 40:629-636 (1996)

Solbrig, M.V. Koob, G.F. Joyce, J.N. Lipkin, W.I. A neural substrate for hyperactivity in Borna disease: changes in brain dopamine receptors. Virology 222:332-338 (1996)

Solbrig, M.V. The history and neurology of hantaviral infectioins. Neurol. Infect. Epidemiol. 2:129-134 (1997)

Solbrig, M.V. and Naviaux, R.K. Review of the neurology and biology of Ebola and Marburg virus infections. Neurol. Infect. Epidemiol. 2:5-12 (1997)

Solbrig, M.V. Lassa fever and central nervous system diseases: a review. Neurol. Infect. Epidemiol. 2:13-18 (1997)

Solbrig, M.V. Koob, G.F. Lipkin, W.I. Cocaine sensitivity in Borna Disease virus-infected rats. Pharmacol Biochem Behavior 59:1047-1052 (1998)

Solbrig, M.V. Koob, G.F. Lipkin, W.I. Oral dyskinesias and dystonia in rats infected with Borna Disease virus: a model for tardive dyskinetic syndromes. Molecular Psychiatry 4:310-312 (1999)

Solbrig, M.V. Koob, G.F. Parsons, L.H. Horscroft, N. Kadota, T. Briese, T. Lipkin, W.I. Neurotrophic factor expression following CNS viral injury produces enhanced sensitivity to psychostimulants: potential mechanism for addiction vulnerability. J. Neurosci. 20:RC104:1-6 (2000)

Solbrig, M.V. Schlaberg, R. Briese, T. Horscroft, N. Lipkin, W.I. Neuroprotection and reduced microglial proliferation in ribavirin treated Bornavirus infected rats Antimicrob. Agents Chemother. 46:2287-91 (2002)

Solbrig, M.V. Koob, G. F., Lipkin, W. I. Key role for enkephalinergic tone in cortico-striatal-thalamic function Eur. J. Neurosci. 16:1819-1822 (2002)

Solbrig, M.V. Koob, G.F. Neuropharmacological sequelae of Borna Disease Virus. Pharm. Biochem. Behav.. 74: 777-787 (2003)

Nash, J.M., Collins, B., Harvey, R., Krishnan-Sarin, S., Loughlin, S., Miner, C., Shenassa, E., Solbrig, M., Spirito, A., Unger, J. Training the transdisciplinary scientist. A general framework applied to tobacco use behavior. Nicotine & Tob. Res. 5 Suppl 1:S41-53 (2003)

Solbrig, M.V. Koob, G.F. Borna Disease Virus: Neuropharmacological effects of CNS viral infection. Current Neuropharmacology 1:341-350 (2003)

Solbrig, M.V. Koob, G.F. Epilepsy, CNS viral injury and dynorphin. Trnds Pharmacol. Sci. 25:98-103 (2004)

Solbrig, M.V. Adrian, R., Baratta, J., Piomelli, D., Giuffrida, A. Role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Exp. Neurol.194:355-362 (2005)

Solbrig, M.V. Adrian, R., Baratta, J., Lauterborne, J., Koob, G.F. Kappa opioid control of seizures by a virus in an animal model. Brain 129:642-654 (2006)

Solbrig, M.V. Adrian, R., Chang, D.Y., Perng, G.-C. Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model. Neurobiol. Dis 23:612-620 (2006)

Solbrig, M.V. Adrian, R., Wechsler, S.L., Koob, G.F. Activation of potassium M currents have anticonvulsant actions in two rat models of encephalitis. Eur. J. Pharmacol. 555(1):23-29 (2007)

Bortolato, M., Solbrig, M.V. The price of seizure control: dynorphins in interictal and postictal psychosis Psychiatry Res. 151(1-2):139-143 (2007)

Solbrig, M.V. Gilliam, S., Honarmand, S., Tureen, J., Bollen, A., Anderson, L.J., Glaser, C.A. Encephalitis and refractory status epilepticus: The search for infectious causes (submitted)

Solbrig, M.V. Hasso, A.N., Jay, C.A. CNS viruses-diagnostic approach. Neuroimaging Clinics of North America (in press)
   
Grant Novartis- Phase III Clinical development: A 24 month double-blind, randomized, multicenter, placebo-controlled, parallel-grouo study comparing the efficacy and safety of 0.5 mg and 1.25 mg findolimod (FTY720) administered orally once daily vs placebo in patients with relapsing-remitting multiple sclerosis, 01/01/07-12/31/08
   
Professional
Societies
American Academy of Neurology 1982-4, 2004-present
American Neurological Association 2006-present
National AIDS Committee of Sierra Leone 1988-1989
Society for Neurosciences 1996-present
American Society for Virology 1998-present
International Society for Neurovirology 2003-present
   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=5445
   
Last updated 08/31/2007